Press release
Huateng Pharma to Showcase Extensive PEG Derivatives and CDMO Capabilities at CPHI Japan 2025
Changsha, China - 18 March 2025 - Hunan Huateng Pharmaceutical Co., Ltd., a global leader in PEG derivatives and CDMO services for APIs and intermediates, is pleased to announce its participation in CPHI Japan 2025. The company will exhibit its comprehensive product lines and cutting-edge capabilities at Booth No. 4X-06, located at Tokyo Big Sight, Tokyo, Japan, from April 9th to 11th, 2025.Huateng Pharma is dedicated to providing robust support to the biopharmaceutical and chemical pharmaceutical industries. With a strong foundation in PEG technology and state-of-the-art CDMO facilities, the company offers a seamless transition from R&D laboratory supply to commercial-scale production.
Key Product Highlights:
PEG Derivatives
oA vast inventory of over 3000 high-quality PEG derivatives.
oMonodispersed PEG linkers and multi-arm PEGs.
oScalable production from R&D to GMP commercial levels.
oApplications spanning ADCs, PROTACs, LNP drug delivery, medical devices, and more.
Pharmaceutical Intermediates
oComprehensive process development and scale-up production.
oFlexible capacities ranging from grams to multi-tons.
Veterinary APIs & intermediates: Fluralaner and related intermediates.
Cosmetic Intermediates: Tetrahydrocurcumin, Piroctone Olamine, and other high-purity ingredients for the cosmetic industry.
"We are excited to showcase our extensive range of PEG derivatives and CDMO capabilities at CPHI Japan 2025," said Sonia Lee, Head of BD at Huateng Pharma. "We sincerely welcome all attendees to visit our booth and explore how we can collaborate to drive innovation and achieve operational success. Our team will be on hand to provide detailed information and discuss tailored solutions to meet your specific needs."
Huateng Pharma's commitment to quality and innovation makes it a trusted partner for companies seeking reliable and efficient solutions. The company's expertise in PEG technology and CDMO services enables customers to accelerate their drug development and manufacturing processes.
Visit Huateng Pharma at CPHI Japan 2025, Booth No. 4X-06, to discover how we can contribute to your success.
For more information, please visit:
Website: https://us.huatengsci.com/
Email: sales@huatengusa.com
Website: https://us.huatengsci.com
Email: sales@huatengusa.com
Zip code: 410205
Telephone: +86 731 89916275
Fax: + 86 731-82251112 EXT 818
Headoffice: Building E1, Lugu Corporation Plaza, High-Tech Industrial Development Zone, Changsha City, Hunan Province, P.R.China
About Hunan Huateng Pharmaceutical Co., Ltd.
Hunan Huateng Pharmaceutical Co., Ltd. is a world-leading supplier of PEG derivatives and CDMO for APIs and intermediates, supporting the pharmaceutical industry from R&D to commercial production. With a focus on quality, innovation, and customer service, Huateng Pharma is dedicated to providing comprehensive solutions to meet the evolving needs of its global clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Huateng Pharma to Showcase Extensive PEG Derivatives and CDMO Capabilities at CPHI Japan 2025 here
News-ID: 3932473 • Views: …
More Releases from Hunan Huateng Pharmaceutical Co., Ltd.
Huateng Pharma Introduces New Cosmetic Actives to Meet Growing Demand for High-P …
Huateng Pharma, a global leader in specialty chemicals, has expanded its product portfolio to include a new line of high-quality cosmetic ingredients. The launch addresses the increasing demand for effective, safe, and readily available actives for modern skincare and personal care formulations.
The new offerings are now available for immediate delivery and include several key ingredients:
Diethylamino Hydroxybenzoyl Hexyl Benzoate (CAS 302776-68-7): A REACH-registered UVA filter that provides broad-spectrum sun protection. This…
Huateng Pharma Highlights the Pharmaceutical Potential of N-Benzylhydroxylamine …
Hunan Huateng Pharmaceutical Co., Ltd., a leading global supplier of PEG derivatives and pharmaceutical intermediates, is proud to offer high-purity N-Benzylhydroxylamine Hydrochloride (CAS 29601-98-7) to researchers and pharmaceutical developers worldwide. This compound has gained attention for its multifunctional properties and critical role in drug discovery and development.
N-Benzylhydroxylamine Hydrochloride features a unique nitrogen-oxygen (N-O) functional group, which enables its wide-ranging applications in medicinal chemistry, including:
Metal Chelation for Iron Overload Disorders: Its…

Huateng Pharma's mPEG-pALD Receives FDA DMF Filing Approval
Changsha, China - Hunan Huateng Pharmaceutical Co., Ltd. (Huateng Pharma), a global leader in the development and production of high-quality PEG derivatives, is pleased to announce that its mPEG-pALD (20K) has successfully completed its Drug Master File (DMF) filing with the U.S. Food and Drug Administration (FDA), under DMF No. 040600. This achievement highlights Huateng Pharma's dedication to meeting the highest regulatory standards and further strengthens its commitment to supporting…
More Releases for PEG
Biopharma PEG Delivers Innovative PEG Solutions for Enhanced Drug Efficacy
Watertown, MA - October 24, 2024 - Biopharma PEG is excited to announce its extensive offerings of polyethylene glycol (PEG) products, including monofunctional, homobifunctional, heterobifunctional, and multi-arm PEGs, tailored for PEGylation in biopharmaceutical applications. With over 40 PEGylated drugs approved globally, the role of PEGylation in drug development is more critical than ever.
PEGylation provides numerous advantages, such as improved solubility, enhanced stability, and increased circulation time in the bloodstream. By…
Biopharma PEG Expands Multi-Arm PEG Product Line
Biopharma PEG, a leader in PEG derivatives, is excited to announce the expansion of its high-purity Multi-Arm PEG linker product line, catering to the evolving needs of the medical and bioorganic fields. These advanced PEG linkers are available in various functional groups and molecular weights ranging from 1k to 40k, offering unmatched versatility and performance for research and development in cutting-edge medical applications.
"Biopharma PEG is committed to delivering high-purity multi-arm…
Biopharma PEG Supplies PEG Products Used For Infectious Disease Vaccines
As of January 1, 2023, global vaccine development includes a total of 966 vaccine candidates, of which 23% (220) are traditional inactivated or attenuated vaccines. Advances in molecular technology have facilitated the development of other platforms, such as recombinant protein vaccines, nucleic acid vaccines, and viral vector vaccines, which have further diversified global vaccine development.
Recombinant protein vaccines accounted for the largest proportion of all pipeline in development, 22% (215), due…
Biopharma PEG Supplies PEG Products For Click Chemistry Reactions
What is "click chemistry"? "Click Chemistry", this is a literary name given to this kind of reaction by the Nobel Prize winner K.Burry Sharless, when the cards are put together, "click" (click). Simply put, it is to add two structures to two molecules respectively, and these two structures can be specifically combined to synthesize the required chemical molecules. One of the most famous click-chemistry reactions is the Cu-catalyzed azide-alkyne cycloaddition…
Biopharma PEG Develops PEG Linkers for Antibody Drug Conjugates
Antibody-drug conjugate (ADC) is one of the fastest growing fields in tumor therapy, which consists of monoclonal antibody (Antibody), linker (Linker) and active drug (Payload). So far, there are only 15 drugs on the market in the world. However, with the development of some perfect antibody modification techniques, advanced site-specific coupling techniques and powerful small-molecule toxins, ADC drug research has mushroomed and a large number of ADC drugs are in…
Biopharma PEG Provides Multi-arm PEG Derivatives Crosslinked Into Hydrogels
Polyethylene (ethylene glycol) is a hydrophilic polymer that can have a very high water content when cross-linked into a network. Polyethylene glycol (PEG) is a suitable material for biological applications because it does not normally elicit an immune response. Since the 1970s, PEG has been used to modify therapeutic proteins and peptides in order to increase their solubility, reduce their toxicity, and prolong their cyclic half-lives. In the late 1970s,…